Log in or Sign up for Free to view tailored content for your specialty!
Gastroenterology News
VIDEO: Rebyota effective in prevention of recurrent C. diff, even in higher risk patients
PHILADELPHIA — Rebyota was safe and effective at 8 weeks and up to 6 months in patients with recurrent Clostridioides difficile infection, many of whom had other gastrointestinal comorbidities and risk factors, according to data presented.
Atmo capsule may offer ‘potential replacement’ for nixed SmartPill in motility disorders
PHILADELPHIA — An ingestible gas-sensing capsule from Atmo Biosciences showed “substantial agreement” with the discontinued Medtronic wireless motility device for measuring regional transit times in gastrointestinal motility disorders.
Log in or Sign up for Free to view tailored content for your specialty!
Colonoscopy, stool-based screening outperforms blood test for colorectal cancer detection
Both colonoscopies and stool-based tests for colorectal cancer screening may be more efficient and cost-effective compared with blood-based tests, study findings published in Annals of Internal Medicine showed.
No increased risk for IBD flare 1 year after gender-affirming hormone therapy
PHILADELPHIA — Although there was no overall increased risk for flare 1 year after gender-affirming hormone therapy in patients with inflammatory bowel disease, active IBD and receiving testosterone increased the likelihood of a flare.
‘High prevalence’ of extremity repetitive use injuries reported among endoscopists
PHILADELPHIA — A “high prevalence” of extremity repetitive use injury symptoms were reported among endoscopists, which negatively affected performance, according to a presenter at the ACG Annual Scientific Meeting.
‘No clear efficacy benefit’ to combining bezlotoxumab with FMT in IBD, recurrent C. diff
PHILADELPHIA — Bezlotoxumab in combination with fecal microbiota transplantation did not further reduce recurrence of Clostridioides difficile infection in patients with inflammatory bowel disease, according to data presented here.
VIDEO: Risankizumab bests placebo at 52 weeks in UC, regardless of induction outcomes
PHILADELPHIA — Risankizumab outperformed placebo in endoscopic improvement and remission through 52 weeks of maintenance therapy in moderately to severely active ulcerative colitis, regardless of induction outcomes, according to data.
Approach reduces pain, opioid demand among people with pancreatic cancer
The delivery of transvascular energy reduced pain and improved quality of life within 7 days among patients with pancreatic cancer, according to a topline data announcement.
The leading edge: New therapies redefine PBC treatment landscape
Recent advancements have been made in the treatment of primary biliary cholangitis, particularly for patients who do not respond adequately to first-line treatment.
AI-assisted GI Genius ‘had no impact’ on serrated polyp detection in positive stool tests
PHILADELPHIA—An AI-assisted endoscopy module minorly improved adenoma detection during colonoscopy, but “had no impact” on serrated polyp detection in patients with positive stool tests, a presenter said at the ACG Annual Scientific Meeting.
-
Headline News
Rise in alcohol use during pandemic endures as 'an alarming public health issue'
November 14, 20242 min read -
Headline News
AI identified patient messages sent by proxies, but also broke confidentiality
November 14, 20242 min read -
Headline News
Diabetes inequities persist worldwide, especially for low-, middle-income countries
November 14, 20243 min read
-
Headline News
Rise in alcohol use during pandemic endures as 'an alarming public health issue'
November 14, 20242 min read -
Headline News
AI identified patient messages sent by proxies, but also broke confidentiality
November 14, 20242 min read -
Headline News
Diabetes inequities persist worldwide, especially for low-, middle-income countries
November 14, 20243 min read